ELMIRON ® -100 mg (pentosan polysulfate sodium) Capsules

Manufacturer
Physicians Total Care, Inc.
Effective date
2010-03-08
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 20:10:09

Label at a glance#

ProductElmiron
Active ingredientPENTOSAN POLYSULFATE SODIUM
Label structure16 sections

Indications and uses

ELMIRON ® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

Dosage and administration

The recommended dose of ELMIRON ® is 300 mg/day taken as one 100 mg capsule orally three times daily. The capsules should be taken with water at least 1 hour before meals or 2 hours after meals. Patients receiving ELMIRON ® should be reassessed after 3 months. If improvement has not occurred and if limiting adverse events are not present, ELMIRON ® may be continued for another 3 months. The clinical value and risk...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

PRESCRIBING INFORMATION

DESCRIPTION

DESCRIPTION SECTION

Pentosan polysulfate sodium is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. It is a white odorless powder, slightly hygroscopic and soluble in water to 50% at pH 6. It has a molecular weight of 4000 to 6000 Dalton with the following structural formula:

Chemical Structure
Chemical Structure

ELMIRON® is supplied in white opaque hard gelatin capsules containing 100 mg pentosan polysulfate sodium, microcrystalline cellulose, and magnesium stearate. It also contains pharmaceutical glaze (modified) in SD-45, synthetic black iron oxide, FD&C Blue No. 2 aluminum lake, FD&C Red No. 40 aluminum lake, FD&C Blue No. 1 aluminum lake, D&C Yellow No. 10 aluminum lake, n-butyl alcohol, propylene glycol, SDA-3A alcohol, and titanium dioxide. It is formulated for oral use.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

General

SPL UNCLASSIFIED SECTION

Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects. The mechanism of action of pentosan polysulfate sodium in interstitial cystitis is not known.

Pharmacokinetics

PHARMACOKINETICS SECTION

Absorption

SPL UNCLASSIFIED SECTION

In a clinical pharmacology study in which healthy female volunteers received a single oral 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug as a solution under fasted conditions, maximal levels of plasma radioactivity were seen approximately at a median of 2 hours (range 0.6–120 hours) after dosing. Based on urinary excretion of radioactivity, a mean of approximately 6% of a radiolabeled oral dose of pentosan polysulfate sodium is absorbed and reaches the systemic circulation.

Food Effects

SPL UNCLASSIFIED SECTION

In clinical trials, ELMIRON® was administered with water 1 hour before or 2 hours after meals; the effect of food on absorption of pentosan polysulfate sodium is not known.

Distribution

SPL UNCLASSIFIED SECTION

Preclinical studies with parenterally administered radiolabeled pentosan polysulfate sodium showed distribution to the uroepithelium of the genitourinary tract with lesser amounts found in the liver, spleen, lung, skin, periosteum, and bone marrow. Erythrocyte penetration is low in animals.

Metabolism

SPL UNCLASSIFIED SECTION

The fraction of pentosan polysulfate sodium that is absorbed is metabolized by partial desulfation in the liver and spleen, and by partial depolymerization in the kidney to a large number of metabolites. Both the desulfation and depolymerization can be saturated with continued dosing.

Excretion

SPL UNCLASSIFIED SECTION

Following administration of an oral solution of a 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug to groups of healthy subjects, plasma radioactivity declined with mean half-lives of 27 and 20 hours, respectively. A large proportion of the orally administered dose of pentosan polysulfate sodium (mean 84% in the 300 mg group and 58% in the 450 mg group) is excreted in feces as unchanged drug. A mean of 6% of an oral dose is excreted in the urine, mostly as desulfated and depolymerized metabolites. Only a small fraction of the administered dose (mean 0.14%) is recovered as intact drug in urine.

Special Populations

SPL UNCLASSIFIED SECTION

The pharmacokinetics of pentosan polysulfate sodium has not been studied in geriatric patients or in patients with hepatic or renal impairment. See also PRECAUTIONS-Hepatic Insufficiency.

Drug-Drug Interactions

SPL UNCLASSIFIED SECTION

In a study in which healthy subjects received pentosan polysulfate sodium 100 mg capsule or placebo every 8 hours for 7 days, and were titrated with warfarin to an INR of 1.4 to 1.8, the pharmacokinetic parameters of R-warfarin and S-warfarin were similar in the absence and presence of pentosan polysulfate sodium. INR for warfarin + placebo and warfarin + pentosan polysulfate sodium were comparable. See also PRECAUTIONS on the use of ELMIRON® in patients receiving other therapies with anticoagulant effects.

Pharmacodynamics

PHARMACODYNAMICS SECTION

The mechanism by which pentosan polysulfate sodium achieves its effects in patients is unknown. In preliminary clinical models, pentosan polysulfate sodium adhered to the bladder wall mucosal membrane. The drug may act as a buffer to control cell permeability preventing irritating solutes in the urine from reaching the cells.

CLINICAL TRIALS

CLINICAL STUDIES SECTION

ELMIRON® was evaluated in two clinical trials for the relief of pain in patients with chronic interstitial cystitis (IC). All patients met the NIH definition of IC based upon the results of cystoscopy, cytology, and biopsy. One blinded, randomized, placebo controlled study evaluated 151 patients (145 women, 5 men, 1 unknown) with a mean age of 44 years (range 18 to 81). Approximately equal numbers of patients received either placebo or ELMIRON® 100 mg three times a day for 3 months. Clinical improvement in bladder pain was based upon the patient's own assessment. In this study, 28/74 (38%) of patients who received ELMIRON® and 13/74 (18%) of patients who received placebo, showed greater than 50% improvement in bladder pain (p=0.005).

A second clinical trial, the physician's usage study, was a prospectively designed retrospective analysis of 2499 patients who received ELMIRON® 300 mg a day without blinding. Of the 2499 patients, 2220 were women, 254 were men, and 25 were of unknown sex. The patients had a mean age of 47 years and 23% were over 60 years of age. By 3 months, 1307 (52%) of the patients had dropped out or were ineligible for analysis, overall, 1192 (48%) received ELMIRON® for 3 months; 892 (36%) received ELMIRON® for 6 months; and 598 (24%) received ELMIRON® for one year.

Patients had unblinded evaluations every 3 months for the patient's rating of overall change in pain in comparison to baseline and for the difference calculated in "pain/discomfort" scores. At baseline, pain/discomfort scores for the original 2499 patients were severe or unbearable in 60%, moderate in 33% and mild or none in 7% of patients. The extent of the patients' pain improvement is shown in Table 1.

At 3 months, 722/2499 (29%) of the patients originally in the study had pain scores that improved by one or two categories. By 6 months, in the 892 patients who continued taking ELMIRON®, an additional 116/2499 (5%) of patients had improved pain scores. After 6 months, the percent of patients who reported the first onset of pain relief was less than 1.5% of patients who originally entered in the study (see Table 2).

Table 1: Pain Scores in Reference to Baseline in Open Label Physician's Usage Study (N=2499)*
Efficacy Parameter3 months† 6 months†
Patient Rating of Overall Change in Pain (Recollection of difference between current pain and baseline pain)‡ N=1161
Median=3
Mean=3.44
CI: (3.37, 3.51)
N=724
Median=4
Mean=3.91
CI: (3.83, 3.99)
Change in Pain/Discomfort Score (Calculated difference in scores at the time point and baseline)§ N=1440
Median=1
Mean=0.51
CI: (0.45, 0.57)
N=904
Median=1
Mean=0.66
CI: (0.61, 0.71)

* Trial not designed to detect onset of pain relief

† CI = 95% confidence interval

‡ 6-point scale: 1 = worse, 2 = no better, 3 = slightly improved, 4 = moderately improved, 5 = greatly improved, 6 = symptom gone

§ 3-point scale: 1 = none or mild, 2 = moderate, 3 = severe or unbearable

Table 2: Number (%) of Patients with New Relief of Pain/Discomfort* in the Open-Label Physician's Usage Study (N=2499)
at 3 months†
(n=1192)
at 6 months‡
(n=892)
Considering only the patients who continued treatment722/1192 (61%)116/892 (13%)
Considering all the patients originally enrolled in the study722/2499 (29%)116/2499 (5%)

* First-time Improvement in pain/discomfort score by 1 or 2 categories

† Number (%) of patients with improvement of pain/discomfort score at 3 months when compared to baseline

‡ Number (%) of patients without pain/discomfort improvement at 3 months who had improvement at 6 months

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

ELMIRON® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients.

WARNINGS

WARNINGS SECTION

None.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

ELMIRON® is a weak anticoagulant (1/15 the activity of heparin). At a daily dose of 300 mg (n = 128), rectal hemorrhage was reported as an adverse event in 6.3% of patients. Bleeding complications of ecchymosis, epistaxis, and gum hemorrhage have been reported (see ADVERSE REACTIONS). Patients undergoing invasive procedures or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to other therapies such as coumarin anticoagulants, heparin, t-PA, streptokinase, high dose aspirin, or nonsteroidal anti-inflammatory drugs) should be evaluated for hemorrhage. Patients with diseases such as aneurysms, thrombocytopenia, hemophilia, gastrointestinal ulcerations, polyps, or diverticula should be carefully evaluated before starting ELMIRON®.

A similar product that was given subcutaneously, sublingually, or intramuscularly (and not initially metabolized by the liver) is associated with delayed immunoallergic thrombocytopenia with symptoms of thrombosis and hemorrhage. Caution should be exercised when using ELMIRON® in patients who have a history of heparin induced thrombocytopenia.

Alopecia is associated with pentosan polysulfate and with heparin products. In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp.

Hepatic Insufficiency

SPL UNCLASSIFIED SECTION

ELMIRON® has not been studied in patients with hepatic insufficiency. Because there is evidence of hepatic contribution to the elimination of ELMIRON®, hepatic impairment may have an impact on the pharmacokinetics of ELMIRON®. Caution should be exercised when using ELMIRON® in this patient population.

Mildly (<2.5 × normal) elevated transaminase, alkaline phosphatase, γ-glutamyl transpeptidase, and lactic dehydrogenase occurred in 1.2% of patients. The increases usually appeared 3 to 12 months after the start of ELMIRON® therapy, and were not associated with jaundice or other clinical signs or symptoms. These abnormalities are usually transient, may remain essentially unchanged, or may rarely progress with continued use. Increases in PTT and PT (<1% for both) or thrombocytopenia (0.2%) were noted.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients should take the drug as prescribed, in the dosage prescribed, and no more frequently than prescribed. Patients should be reminded that ELMIRON® has a weak anticoagulant effect. This effect may increase bleeding times.

Laboratory Test Findings

LABORATORY TESTS SECTION

Pentosan polysulfate sodium did not affect prothrombin time (PT) or partial thromboplastin time (PTT) up to 1200 mg per day in 24 healthy male subjects treated for 8 days. Pentosan polysulfate sodium also inhibits the generation of factor Xa in plasma and inhibits thrombin-induced platelet aggregation in human platelet rich plasma ex vivo. (See PRECAUTIONS-Hepatic Insufficiency Section for additional information.)

Carcinogenicity, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long term carcinogenicity studies of ELMIRON® in F344/N rats and B6C3F1 mice have been conducted. In these studies, ELMIRON® was orally administered once daily via gavage, 5 days per week, for up to 2 years. The dosages administered to mice were 56, 168 or 504 mg/kg. The dosages administered to rats were 14, 42, or 126 mg/kg for males, and 28, 84, or 252 mg/kg for females. The dosages tested were up to 60 times the maximum recommended human dose (MRHD) in rats, and up to 117 times the MRHD in mice, on a mg/kg basis. The results of these studies in rodents showed no clear evidence of drug-related tumorigenesis or carcinogenic risk.

Pentosan polysulfate sodium was not clastogenic or mutagenic when tested in the mouse micronucleus test or the Ames test (S. typhimurium). The effect of pentosan polysulfate sodium on spermatogenesis has not been investigated.

Pregnancy Category B

PREGNANCY SECTION

TERATOGENIC EFFECTS SECTION

Reproduction studies have been performed in mice and rats with intravenous daily doses of 15 mg/kg, and in rabbits with 7.5 mg/kg. These doses are 0.42 and 0.14 times the daily oral human doses of ELMIRON® when normalized to body surface area. These studies did not reveal evidence of impaired fertility or harm to the fetus from ELMIRON®. Direct in vitro bathing of cultured mouse embryos with pentosan polysulfate sodium (PPS) at a concentration of 1 mg/mL may cause reversible limb bud abnormalities. Adequate and well-controlled studies have not been performed in pregnant women. Because animal studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ELMIRON® is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients below the age of 16 years have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

ELMIRON® was evaluated in clinical trials in a total of 2627 patients (2343 women, 262 men, 22 unknown) with a mean age of 47 [range 18 to 88 with 581 (22%) over 60 years of age]. Of the 2627 patients, 128 patients were in a 3 month trial and the remaining 2499 patients were in a long term, unblinded trial.

Deaths occurred in 6/2627 (0.2%) patients who received the drug over a period of 3 to 75 months. The deaths appear to be related to other concurrent illnesses or procedures, except in one patient for whom the cause was not known.

Serious adverse events occurred in 33/2627 (1.3%) patients. Two patients had severe abdominal pain or diarrhea and dehydration that required hospitalization. Because there was not a control group of patients with interstitial cystitis who were concurrently evaluated, it is difficult to determine which events are associated with ELMIRON® and which events are associated with concurrent illness, medicine, or other factors.

Adverse Experience In Placebo-Controlled Clinical Trials of ELMIRON® 100 mg Three Times a Day for 3 Months
Body System/Adverse ExperienceELMIRON®
n=128
Placebo
n=130
CNS Overall Number of Patients* 35
  Insomnia10
  Headache13
  Severe Emotional Lability/Depression21
  Nystagmus/Dizziness11
  Hyperkinesia11
GI Overall Number of Patients* 77
  Nausea33
  Diarrhea36
  Dyspepsia10
  Jaundice01
  Vomiting02
Skin/Allergic Overall Number of Patients* 24
  Rash02
  Pruritus02
  Lacrimation11
  Rhinitis11
  Increased Sweating10
Other Overall Number of Patients* 13
  Amenorrhea01
  Arthralgia01
  Vaginitis11
Total Events1727
Total Number of Patients
Reporting Adverse Events1319

* Within a body system, the individual events do not sum to equal overall number of patients because a patient may have more than one event.

The adverse events described below were reported in an unblinded clinical trial of 2499 interstitial cystitis patients treated with ELMIRON®. Of the original 2499 patients, 1192 (48%) received ELMIRON® for 3 months; 892 (36%) received ELMIRON for 6 months; and 598 (24%) received ELMIRON® for one year, 355 (14%) received ELMIRON® for 2 years, and 145 (6%) for 4 years.

Frequency (1 to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%).

Frequency (≤ 1%):

Digestive: Vomiting, mouth ulcer, colitis, esophagitis, gastritis, flatulence, constipation, anorexia, gum hemorrhage.

Hematologic: Anemia, ecchymosis, increased prothrombin time, increased partial thromboplastin time, leukopenia, thrombocytopenia.

Hypersensitive Reactions: Allergic reaction, photosensitivity.

Respiratory System: Pharyngitis, rhinitis, epistaxis, dyspnea.

Skin and Appendages: Pruritus, urticaria.

Special Senses: Conjunctivitis, tinnitus, optic neuritis, amblyopia, retinal hemorrhage.

Post-Marketing Experience

SPL UNCLASSIFIED SECTION

Rectal Hemorrhage

SPL UNCLASSIFIED SECTION

ELMIRON® was evaluated in a randomized, double-blind, parallel group, Phase 4 study conducted in 380 patients with interstitial cystitis dosed for 32 weeks. At a daily dose of 300 mg (n = 128), rectal hemorrhage was reported as an adverse event in 6.3% of patients. The severity of the events was described as "mild" in most patients. Patients in that study who were administered ELMIRON® 900 mg daily, a dose higher than the approved dose, experienced a higher incidence of rectal hemorrhage, 15%.

Liver Function Abnormality

SPL UNCLASSIFIED SECTION

A randomized, double-blind, parallel group, phase 2 study was conducted in 100 men (51 ELMIRON® and 49 placebo) dosed for 16 weeks. At a daily dose of 900 mg, a dose higher than the approved dose, elevated liver function tests were reported as an adverse event in 11.8% (n = 6) of ELMIRON® treated patients and 2% (n = 1) of placebo treated patients.

OVERDOSAGE

OVERDOSAGE SECTION

Overdose has not been reported. Based upon the pharmacodynamics of the drug, toxicity is likely to be reflected as anticoagulation, bleeding, thrombocytopenia, liver function abnormalities, and gastric distress. (See CLINICAL PHARMACOLOGY and PRECAUTIONS sections.) At a daily dose of 900 mg for 32 weeks (n = 127) in a clinical trial, rectal hemorrhage was reported as an adverse event in 15% of patients. At a daily dose of ELMIRON® 900 mg for 16 weeks in a clinical trial that enrolled 51 patients in the ELMIRON® group and 49 in the placebo group, elevated liver function tests were reported as an adverse event in 11.8% of patients in the ELMIRON® group and 2% of patients in the placebo group. In the event of acute overdosage, the patient should be given gastric lavage if possible, carefully observed and given symptomatic and supportive treatment.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended dose of ELMIRON® is 300 mg/day taken as one 100 mg capsule orally three times daily. The capsules should be taken with water at least 1 hour before meals or 2 hours after meals.

Patients receiving ELMIRON® should be reassessed after 3 months. If improvement has not occurred and if limiting adverse events are not present, ELMIRON® may be continued for another 3 months.

The clinical value and risks of continued treatment in patients whose pain has not improved by 6 months is not known.

HOW SUPPLIED

HOW SUPPLIED SECTION

ELMIRON® is supplied in white opaque hard gelatin capsules imprinted "BNP7600" containing 100 mg pentosan polysulfate sodium. Supplied in:

NDC 54868-4525-2
Bottles of 10 capsules
NDC 54868-4525-1
Bottles of 30 capsules
NDC 54868-4525-3
Bottles of 90 capsules
NDC 54868-4525-0
Bottles of 100 capsules

Storage

STORAGE AND HANDLING SECTION

Store at controlled room temperature 15°–30°C (59°–86°F).

SPL UNCLASSIFIED SECTION

ELMIRON® is a Registered Trademark of Teva Global Respiratory Research, LLC under license to Ortho-McNeil-Janssen Pharmaceuticals, Inc.

© OMJPI 2002,1998

Ortho Women's Health & Urology, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Raritan, New Jersey 08869

Manufactured by:
Janssen Ortho LLC
Gurabo, Puerto Rico 00778

Manufactured for:
Ortho Women's Health & Urology, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Raritan, New Jersey 08869

Revised October 2009

10205900

U.S. Patent #5,180,715


Relabeling and Repackaging by:
Physicians Total Care, Inc.
Tulsa, OK     74146

SPL UNCLASSIFIED SECTION

PHARMACIST: PLEASE DISPENSE ONE PATIENT LEAFLET PER PRESCRIPTION

Patient Leaflet

SPL PATIENT PACKAGE INSERT SECTION

Questions and Answers About

ELMIRON®
(Generic name = pentosan polysulfate sodium)
Capsules

What is the most important information I should know about ELMIRON®?
ELMIRON® (pronounced EL ma ron) is used to treat the pain or discomfort of interstitial cystitis (IC).
 
You must take ELMIRON® as prescribed by your doctor in the dosage prescribed but no more frequently than prescribed.
 
ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding.
 
Call your doctor if you will be undergoing surgery or will begin taking anticoagulant therapy such as warfarin sodium, heparin, high doses of aspirin, or anti-inflammatory drugs such as ibuprofen.

What is ELMIRON®?

ELMIRON® is used to treat the pain or discomfort of interstitial cystitis (IC). It is not known exactly how ELMIRON® works, but it is not a pain medication like aspirin or acetaminophen and therefore must be taken continuously for relief as prescribed.

Who should not take ELMIRON®?

  • Patients undergoing surgery should speak with their doctor about when to discontinue ELMIRON® prior to surgery.
  • ELMIRON® should be used during pregnancy only if clearly needed.

What does your doctor need to know?

  • If you are taking anticoagulant therapy such as warfarin sodium, heparin, high doses of aspirin, or anti-inflammatory drugs such as ibuprofen.
  • If you are pregnant.
  • If you have any liver problems.

How should I take ELMIRON®?

You should take 1 capsule of ELMIRON® by mouth three times a day, with water at least 1 hour before meals or 2 hours after meals. Each capsule contains 100 mg of ELMIRON®.

What should I avoid while taking ELMIRON®?

Anticoagulant therapy such as warfarin sodium, heparin, high doses of aspirin or anti-inflammatory drugs such as ibuprofen until you speak with your doctor.

What are the most common side effects of ELMIRON®?

The most common side effects are hair loss, diarrhea, nausea, blood in the stool, headache, rash, upset stomach, abnormal liver function tests, dizziness and bruising.

Call your doctor if these side effects persist or are bothersome or if there is blood in your stool.

If you suspect that someone may have taken more than the prescribed dose of this medicine, contact your local poison control center or emergency room immediately. This medication was prescribed for your particular condition. Do not use it for another condition or give the drug to others.

This leaflet provides a summary of information about ELMIRON®. Medicines are sometimes prescribed for uses other than those listed in a Patient Leaflet. If you have any questions or concerns, or want more information about ELMIRON®, contact your doctor or pharmacist. Your pharmacist also has a longer leaflet about ELMIRON® that is written for health professionals that you can ask to read.

ELMIRON® is a Registered Trademark of Teva Global Respiratory Research, LLC under license to Ortho-McNeil-Janssen Pharmaceuticals, Inc.

© OMJPI 2002,1998

Ortho Women's Health & Urology, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Raritan, New Jersey 08869

Revised October 2009

PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

ELMIRON®
(pentosan polysulfate sodium)
CAPSULES

Rx only

ELMIRON® is a registered trademark
of IVAX Research, LLC under license to
Ortho-McNeil-Janssen Pharmaceuticals, Inc.

100 mg

Principal Display Panel - 100 mg Bottle LabelPrincipal Display Panel - 100 mg Bottle Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
211140Elmiron 100 MG Oral CapsulePSN2
199498pentosan polysulfate sodium 100 MG Oral CapsulePSN2
211140pentosan polysulfate 100 MG Oral Capsule [Elmiron]SBD2
199498pentosan polysulfate 100 MG Oral CapsuleSCD2
211140Elmiron 100 MG Oral CapsuleSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
PENTOSAN POLYSULFATE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
0fbf7978-a66d-d22e-cf47-78546f9f9c42Product name120140508

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54868-4525-0Elmiron100 in 1 BOTTLECAPSULE, GELATIN COATED1002
54868-4525-1Elmiron30 in 1 BOTTLE, PLASTICCAPSULE, GELATIN COATED302
54868-4525-2Elmiron10 in 1 BOTTLE, PLASTICCAPSULE, GELATIN COATED102
54868-4525-3Elmiron90 in 1 BOTTLE, PLASTICCAPSULE, GELATIN COATED902

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54868-4525ELMIRON (PENTOSAN POLYSULFATE SODIUM) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]24 package rows20101004_c7417e03-5812-4f35-8433-6062d68420fc.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54868-4525-0EA - Each54868-45250c4c44fd-4962-47c0-9a8a-59cf5a3267de12012-07-24
54868-4525-1EA - Each54868-45253ed5539e-0c16-4565-b3d5-1e066133bd7612012-07-24
54868-4525-2EA - Each54868-452544d645a4-1416-4ac6-9b9a-1f9adc5a938312012-07-24
54868-4525-3EA - Each54868-45258c6374de-bd12-4811-a9f1-3513b84eb55712012-07-24
50458-098-01EA - Each50458-0984cce362d-6019-46db-b564-516c67fd909212012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
PENTOSAN POLYSULFATE SODIUMACTIVE INGREDIENT914032762Y2
PENTOSAN POLYSULFATEACTIVE MOIETYF59P8B75R42
ALUMINUM OXIDEINACTIVE INGREDIENTLMI26O69332
BUTYL ALCOHOLINACTIVE INGREDIENT8PJ61P6TS32
CELLULOSE, MICROCRYSTALLINEINACTIVE INGREDIENTOP1R32D61U2
D&C YELLOW NO. 10INACTIVE INGREDIENT35SW5USQ3G2
FD&C BLUE NO. 1INACTIVE INGREDIENTH3R47K3TBD2
FD&C BLUE NO. 2INACTIVE INGREDIENTL06K8R7DQK2
FD&C RED NO. 40INACTIVE INGREDIENTWZB9127XOA2
FERROSOFERRIC OXIDEINACTIVE INGREDIENTXM0M87F3572
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I302
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V32
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JP2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 14 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54868-452554868-4525-0, 54868-4525-1, 54868-4525-2, 54868-4525-3
50458-09850458-098-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 188 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GELIXIR / ORAL0.3 mg/15mlExact identifier — unii+route
21 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOASUSPENSION / ORAL100 mg/5mlExact identifier — unii+route
22 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30POWDER, FOR SUSPENSION / ORAL120 mgExact identifier — unii+route
28 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOACAPSULE, DELAYED RELEASE PELLETS / ORAL0.02 mgExact identifier — unii+route
22 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CAPSULE, DELAYED RELEASE / ORAL1.7 mgExact identifier — unii+route
20 equally ranked IID candidates
BUTYL ALCOHOLBUTYL ALCOHOL8PJ61P6TS3TABLET, EXTENDED RELEASE / ORALNAExact identifier — unii+route
8 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL42 mgExact identifier — unii+route
22 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET, CHEWABLE / ORAL40 mgExact identifier — unii+route
22 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, SUGAR COATED / ORALNAExact identifier — unii+route
28 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, COATED / ORAL16 mgExact identifier — unii+route
20 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, DELAYED RELEASE / ORAL144 mgExact identifier — unii+route
28 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CAPSULE, COATED, EXTENDED RELEASE / ORALNAExact identifier — unii+route
20 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, EXTENDED RELEASE / ORAL173 mgExact identifier — unii+route
28 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDCAPSULE, LIQUID FILLED / ORAL0.08 mgExact identifier — unii+route
22 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDTABLET / ORAL27.53 mgExact identifier — unii+route
22 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDCAPSULE, DELAYED RELEASE PELLETS / ORAL0.01 mgExact identifier — unii+route
22 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOACAPSULE, COATED, EXTENDED RELEASE / ORALNAExact identifier — unii+route
22 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GSUSPENSION, EXTENDED RELEASE / ORAL1 mgExact identifier — unii+route
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61USUSPENSION / ORAL1600 mgExact identifier — unii+route
25 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDCAPSULE, EXTENDED RELEASE / ORAL1 mgExact identifier — unii+route
22 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPTABLET, ORALLY DISINTEGRATING / ORAL6 mgExact identifier — unii+route
22 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30SUSPENSION / ORAL64 mgExact identifier — unii+route
28 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDTABLET, EXTENDED RELEASE / ORAL4 mgExact identifier — unii+route
22 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDCAPSULE / ORAL26.3 mgExact identifier — unii+route
22 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPCAPSULE / ORAL72 mgExact identifier — unii+route
22 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30LOZENGE / ORAL420 mgExact identifier — unii+route
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30GRANULE / ORAL629 mgExact identifier — unii+route
28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, FOR SUSPENSION / ORAL20100 mgExact identifier — unii+route
25 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET, EXTENDED RELEASE / ORAL2.22 mgExact identifier — unii+route
22 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTROCHE / ORAL300 mgExact identifier — unii+route
25 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL47 mgExact identifier — unii+route
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30PELLET / ORAL24 mgExact identifier — unii+route
28 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPSUSPENSION / ORAL113 mgExact identifier — unii+route
22 equally ranked IID candidates
FERROSOFERRIC OXIDEFERROSOFERRIC OXIDEXM0M87F357CAPSULE / ORAL11 mgExact identifier — unii+route
10 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE, EXTENDED RELEASE / ORAL117 mgExact identifier — unii+route
28 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOADROPS / ORALNAExact identifier — unii+route
22 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GPOWDER, FOR SOLUTION / ORALNAExact identifier — unii+route
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UGRANULE, DELAYED RELEASE / ORAL789.6 mgExact identifier — unii+route
25 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, DELAYED RELEASE PARTICLES / ORAL580 mgExact identifier — unii+route
25 equally ranked IID candidates
FERROSOFERRIC OXIDEFERROSOFERRIC OXIDEXM0M87F357TABLET, FILM COATED / ORAL0.2 mgExact identifier — unii+route
10 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GPOWDER / ORAL48 mgExact identifier — unii+route
21 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPCAPSULE, COATED / ORAL17 mgExact identifier — unii+route
22 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UPELLET / ORAL1140 mgExact identifier — unii+route
25 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, COATED / ORAL920 mgExact identifier — unii+route
25 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GCAPSULE, DELAYED RELEASE / ORAL1 mgExact identifier — unii+route
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, DELAYED RELEASE / ORAL2210 mgExact identifier — unii+route
25 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPCAPSULE, DELAYED RELEASE / ORAL55 mgExact identifier — unii+route
22 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, ORALLY DISINTEGRATING / ORAL187 mgExact identifier — unii+route
28 equally ranked IID candidates
FERROSOFERRIC OXIDEFERROSOFERRIC OXIDEXM0M87F357POWDER, FOR SUSPENSION / ORALNAExact identifier — unii+route
10 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPCAPSULE, COATED PELLETS / ORAL4.4 mgExact identifier — unii+route
22 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route
20 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPTABLET, FILM COATED, EXTENDED RELEASE / ORAL11 mgExact identifier — unii+route
22 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET, FILM COATED / ORAL2.5 mgExact identifier — unii+route
22 equally ranked IID candidates
ALUMINUM OXIDEALUMINUM OXIDELMI26O6933TABLET / ORALNAExact identifier — unii+route
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii+route
28 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPPOWDER / ORAL2 mgExact identifier — unii+route
22 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GTABLET, CHEWABLE / ORAL4 mgExact identifier — unii+route
21 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPTABLET, EXTENDED RELEASE / ORAL90 mgExact identifier — unii+route
22 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL1576 mgExact identifier — unii+route
25 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30GRANULE, FOR SUSPENSION / ORAL14 mgExact identifier — unii+route
28 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N020193-001ELMIRONPENTOSAN POLYSULFATE SODIUM100MGCAPSULE / ORALRLD, RS1996-09-26

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26d4dbc9d85df4…
2026-10-15 13:18:302026-09N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26c2088c7a36db…
2026-09-14 22:38:342026-08N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-2684e616aacf4f…
2026-08-18 06:07:402026-07N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-2631067a03dcf5…
2025-08-23 18:47 UTC2025-08N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-266a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-2603ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-262680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-265bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-2679d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-261e350fbaab3a…
2024-05-31 18:47 UTC2024-05N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-268072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-265c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-265d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-264b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-2674a2ff9319b5…
2022-03-09 01:35 UTC2022-03N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-2687673890dc5c…
2021-03-12 10:30 UTC2021-03N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-265aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-268869cabd3fbd…
2020-11-12 02:37 UTC2020-11N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26c0c555d07b60…
2019-12-14 00:12 UTC2019-12N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-263f01610625f2…
2019-09-15 20:21 UTC2019-09N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26b00525d2431f…
2019-07-19 19:46 UTC2019-07N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-266a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-261c564ffb4f44…
2023-12-20 04:57 UTC2023-12N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-269b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-263f0d92c62455…
2023-05-13 08:27 UTC2023-05N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-26053a50430f4f…
2023-01-26 05:58 UTC2023-01N020193-001ELMIRON100MGCAPSULE / ORALRLD, RS1996-09-263bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ELMIRONPENTOSAN POLYSULFATE SODIUMJanssen Pharmaceuticals, Inc.f0ba651e-3d8a-11df-8fbe-119855d895932024-09-18Warnings, Adverse reactionsExact identifier
ndc (package): 50458-098-01
ndc11 (package): 50458009801
373589f7-8b10-4196-a4ce-f80ea3f086c2c7417e03-5812-4f35-8433-6062d68420fc2010-03-08Warnings, Adverse reactionsExact identifier
spl id: 373589f7-8b10-4196-a4ce-f80ea3f086c2
spl set id: c7417e03-5812-4f35-8433-6062d68420fc

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.